Dennis,
The old morning rush, here. For what it's worth, this announcement is simply the findings for ATIS'dermagraft, not the FDA approval. However, if the news is good, odds are within6 months
there will be FDA approval....expedited approval process already set. Dermagraft would be their main baby, with a much larger revenue stream than dermagraft TC would have, although this one
is scheduled for agenda of FDA 11/19. Other products are still a ways behind, although with good news, it would look like they're really rolling and keeping the pipeline goind...likely IDE before end
of year for study on cartilage replacement in human knee,etc. A lot of the price is based on the value of dermagraft, though, like all growth stocks are...based on future earnings potential. With bad news
the value plunges, by around 50% would be my best guess. With good news, possibly the same up, with continued growth over the next 2 years. I'll let you know more as I learn more, but I expect the odds
are better than 60% chance of the news being good.
BTW, it's RAINing as we speak. Good omen.
Regards,
Marshall |
